Biotricity, Inc. (BTCY) Stock Price & Analysis
Biotricity, Inc. (BTCY) closed at USD 0.06 on Thursday, October 15, 2026, up 2.80% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.05; the Oct 15, 2026 session ranged USD 0.06–0.06 on volume of 1,100 shares. Market capitalization is $1.10M, with a 52-week range of USD 0.04–0.75 (OQB). Source: Nexqual, retrieved October 16, 2026 at 06:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BTCY.md
Key facts (BTCY)
- Last four reported quarters (through Jun 30, 2026): revenue $16.4M, net income -$2.7M (-16.4% margin) (SEC filings).
- Analysts: None.
- Total return with dividends: 1Y -91.9% vs S&P 500 +18.1%; 5Y -99.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD —, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BTCY)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $7.7M | $9.6M | $12.1M | $13.8M | $16.0M | $16.4M |
| Gross profit | $4.6M | $5.4M | $8.4M | $10.6M | $12.9M | — |
| Operating income | -$16.7M | -$15.4M | -$8.8M | -$2.4M | $1.7M | $1.6M |
| Net income | -$29.1M | -$18.7M | -$14.1M | -$8.4M | -$2.4M | -$2.7M |
| EPS (diluted) | — | -$2.26 | -$1.66 | -$0.56 | -$0.12 | — |
| Free cash flow | -$15.2M | — | — | — | — | — |
| Gross margin | 59.7% | 56.5% | 69.3% | 76.6% | 80.9% | — |
| Operating margin | -218.8% | -159.9% | -73.2% | -17.8% | 10.6% | 9.6% |
| Net margin | -380.8% | -193.6% | -116.8% | -61.1% | -15.0% | -16.4% |
| Revenue growth | +126.0% | +26.0% | +25.2% | +14.3% | +16.0% | — |
| Cash + short-term investments | $12.1M | $570K | $786K | $365K | $150K | — |
Fiscal years end Mar. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BTCY)
P/S 0.1x · Earnings yield -243.78%
Analysts (BTCY)
Consensus None.
Total return (dividends reinvested) (BTCY)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -91.9% | -99.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -92.0% | -68.5% |
| Volatility (annualized) | 128.5% | 106.0% |
| Max drawdown | -93.1% (Oct 2025→Oct 2026) | -99.8% (Dec 2021→Oct 2026) |
Key Statistics (as of October 16, 2026 at 06:43 UTC)
| Price | USD 0.06 |
|---|---|
| Change | ▲ 2.80% (up) |
| Previous Close | USD 0.05 |
| Open | USD 0.06 |
| Day Range | USD 0.06 – 0.06 |
| 52-Week Range | USD 0.04 – 0.75 |
| Volume | 1,100 shares |
| Market Cap | $1.10M |
| Exchange | OQB |
Technical Analysis (BTCY)
Nexqual's technical model rates BTCY "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of October 16, 2026 at 06:43 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 34.26 (neutral) |
| vs SMA50 | Below (USD 0.09) |
| MACD | -0.01 (negative) |
Analyst Ratings (BTCY)
Wall Street analysts rate BTCY "None", per Nexqual as of October 16, 2026 at 06:43 UTC.
| Consensus Rating | None |
|---|
Earnings (BTCY)
| Next Earnings Date | 2026-11-12 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -0.03 vs est -0.08 ▲ beat |
| 2025-06-30 | USD -0.03 vs est -0.09 ▲ beat |
| 2025-03-31 | USD 0.02 vs est -0.1 ▲ beat |
Source: Nexqual, October 16, 2026 at 06:43 UTC.
Financials & Fundamentals (BTCY)
| Total Revenue | $16.40M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +10.40% |
| Gross Margin | +81.47% |
| Operating Margin | +3.70% |
| Profit Margin | -16.41% |
| Current Ratio | 0.15 |
| Total Cash | $1.77M |
| Total Debt | $26.93M |
Source: Nexqual, October 16, 2026 at 06:43 UTC.
Financial Health Score (BTCY)
Nexqual rates Biotricity, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 06:43 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Mixed — $2M cash vs $27M debt |
| Cash Flow | Weak — Operating cash flow -$719K (FY ended Mar 2026, 10-K) |
| Efficiency | Mixed — No data |
Ownership (BTCY)
| Insider Ownership | +1.18% |
|---|---|
| Institutional Ownership | +1.22% |
| Shares Outstanding | 19.91M |
| Float | 17.93M |
| Short % of Float | +2.35% |
Source: Nexqual, October 16, 2026 at 06:43 UTC.
Leadership (BTCY)
Biotricity, Inc. is led by Waqaas Al-Siddiq (age 40), Founder, President, CEO & Chairman, per Nexqual as of October 16, 2026 at 06:43 UTC.
| Founder, President, CEO & Chairman | Waqaas Al-Siddiq (age 40) |
|---|---|
| Chief Financial Officer | S. John Ayanoglou (age 59) |
| Senior Director of Operations | Amjad Talpur |
| Vice President of Sales & Strategy | Matt Zabel |
| Executive Vice President of Healthcare Solutions | Fareeha Siddiqui |
Major Backers & Investors (BTCY)
Notable institutional backers of Biotricity, Inc. include Strengthening Families & Communities, LLC , according to Nexqual as of October 16, 2026 at 06:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Strengthening Families & Communities, LLC | 0.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.41% |
Source: Nexqual, October 16, 2026 at 06:43 UTC.
From Biotricity, Inc.'s Latest SEC 10-K Filing (filed 2026-07-14)
Key Strengths & Strategy (as disclosed to the SEC)
- We then expanded our sales force and geographic footprint.   In 2021, we received a 510(k) clearance from the FDA for our Bioflux Software II System, engineered to improve workflows and reduce estimated review time from 5 minutes to 30 seconds.
- We have already established a strong foothold, having already built a powerful proprietary cardiac AI model that combines Google's TensorFlow, AWS infrastructure, big data and a continuous learning engine.
- Cardiac disease is ranked as the number one chronic care disease in the US and most markets globally, making our technology useful across the globe.
- To commence commercialization, we ordered device inventory from our FDA-approved manufacturer and hired a small, captive sales force, with deep experience in cardiac technology sales; we expanded on our limited market release, which identified potential anchor clients who could be early adopters of our technology.
Partnerships
- This adds a layer of differentiation and competitive advantage as customer can deal with one vendor as opposed to multiple vendors that they have to integrate.   Intellectual Property   We primarily rely on trade secret protection for our proprietary information.
- To further expand our market reach, we have partnered with leading distributors and GPOs.   COM   The Bioflux and Biocore Pro solutions are deployed into physicians' offices, clinics, hospitals, and IDTFs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ESTA | Establishment Labs Holdings Inc | USD 61.36 | ▲ 4.98% |
| ALMR | Alamar Biosciences, Inc. | USD 27.42 | ▲ 16.58% |
| INSP | Inspire Medical Systems, Inc. | USD 70.12 | ▲ 1.83% |
| BFLY | Butterfly Network, Inc. | USD 7.85 | ▼ 3.09% |
| AXGN | AxoGen, Inc. | USD 35.63 | ▼ 1.49% |
| UFPT | UFP Technologies, Inc. | USD 297.19 | ▲ 0.99% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 06:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt